Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0851
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer ; day:27 ; month:8 ; year:2020 ; pages:1-13
Cancer immunology immunotherapy ; (27.8.2020), 1-13

Creator
Leary, Alexandra
Genestie, Catherine
Blanc-Durand, Félix
Gouy, Sébastien
Dunant, Ariane
Maulard, Amandine
Drusch, Françoise
Cheaib, Bianca
Michels, Judith
Bentivegna, Enrica
LeFormal, Audrey
Mesnage, Soizick
Morice, Philippe
Pautier, Patricia
Khairallah, Aya S.
Contributor
SpringerLink (Online service)

DOI
10.1007/s00262-020-02670-0
URN
urn:nbn:de:101:1-2020101602512970037387
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Leary, Alexandra
  • Genestie, Catherine
  • Blanc-Durand, Félix
  • Gouy, Sébastien
  • Dunant, Ariane
  • Maulard, Amandine
  • Drusch, Françoise
  • Cheaib, Bianca
  • Michels, Judith
  • Bentivegna, Enrica
  • LeFormal, Audrey
  • Mesnage, Soizick
  • Morice, Philippe
  • Pautier, Patricia
  • Khairallah, Aya S.
  • SpringerLink (Online service)

Other Objects (12)

Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Adjuvant vs Neoadjuvant Chemotherapy In Advanced Ovarian Cancer

Adjuvant vs Neoadjuvant Chemotherapy In Advanced Ovarian Cancer

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma

Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study

Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study

Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience

Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience

Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience

Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience

Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience

Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience

Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer

Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer

Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

Neo-adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Prospective, Randomized Study

Neo-adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Prospective, Randomized Study

Related objects